A randomized, parallel-group, single-center clinical study to examine the safety and effectiveness between argatroban and unfractionated heparin as anticoagulation in combination with clopidogrel and aspirin in coronary heart disease patients with moderate to high bleeding risk undergoing elective percutaneous coronary intervention.

Trial Profile

A randomized, parallel-group, single-center clinical study to examine the safety and effectiveness between argatroban and unfractionated heparin as anticoagulation in combination with clopidogrel and aspirin in coronary heart disease patients with moderate to high bleeding risk undergoing elective percutaneous coronary intervention.

Completed
Phase of Trial: Phase IV

Latest Information Update: 29 Jul 2014

At a glance

  • Drugs Argatroban (Primary) ; Aspirin; Clopidogrel; Heparin
  • Indications Coronary artery disease; Embolism and thrombosis; Unstable angina pectoris
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 21 May 2012 Planned end date (31 Dec 2012) added as reported by Chinese Clinical Trial Register.
    • 16 Dec 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top